Zoetis: A High-Quality Compounder Now On Sale?
1. ZTS faces pressure from reduced clinic traffic and companion-animal demand. 2. Revenue from livestock rose 10%, driven by vaccine demand. 3. Recent product approvals broaden future offerings despite narrowed revenue guidance. 4. ZTS stock available at a 35% discount compared to last year. 5. Stock can decline substantially despite strong fundamentals due to market changes.